SUGAMMADEX is a reversal for deep paralysis induced by rocuronium as neuromuscular blocker in laparoscopic surgery

SUGAMMADEX IN REVERSAL OF PROFOUND NEUROMUSCULAR BLOCKADE IN LAPAROSCOPIC SURGERY - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/02/062639

Enrollment

Registered

2024-02-14

Start date

Unknown

Completion date

Unknown

Last updated

2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Intervention1: Sugammadex: Degree of neuromuscular block will be monitored using Neuromuscular monitoring – Post tetanic count (PTC)Train Of Four (TOF) at the end of the surgery, depending on TOF – Su

Eligibility

Inclusion criteria

Inclusion criteria: 1 Patients undergoing laparoscopic surgery 2 ASA 1,2 3 Age-18 years – 60 years

Exclusion criteria

Exclusion criteria: 1 Patients refusal to participate in the study 2 ASA-3 and above 3 Renal and liver impairment 4 Known hypersensitivity to any drugs

Design outcomes

Primary

Measure	Time frame
To assess the effects of sugammadex as reversal for rocuronium induced neuromuscular blockade in laparoscopic surgery using neuromuscular monitorTimepoint: 24 hours	—

Secondary

Measure	Time frame
Adverse effects of Sugammadex intraoperatively and postoperatively, and complete reversal of deep neuromuscular blockade by sugammadex in laparoscopic surgery complete reversal of deep neuromuscular blockade by sugammadex in laparoscopic surgeryTimepoint: 24 hours	—

Countries

India

Contacts

Public ContactM Bastina Jenoffia

Tagore Medical College And Hospital, Chennai

dr.jenoffia@gmail.com9176472143

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026